With a market cap of more than $243 billion, AbbVie (NYSE: ABBV) is one of the largest pharmaceutical companies on the planet. As an investment, its shares have outperformed the market over the past five years with a total return of 175% against the market's 107%.
Will the future be as lucrative for shareholders? Or will headwinds to its revenue growth end up spoiling the party? In my view, AbbVie is probably going to be successful in the long term, but the next few years will be quite challenging.
Image source: Getty Images.
Source Fool.com